NuVasive Loses Brand-Name Case To Neurovision, Vows Appeal
* Jury awards $60 mln as damages to plaintiff
* NuVasive intends to appeal verdict
Oct 27 (Reuters) – A U.S. district court ruled against medical device maker NuVasive Inc (NUVA.O) regarding the use of the brand name of a spinal-surgery device, and awarded $60 million as damages to the plaintiff.
NuVasive, which intends to appeal the verdict, said the damages amount is subject to change at the judge’s discretion as well as based on additional rulings.
The company does not expect any disruption to sales based on this verdict.
The case relates solely to the use of the NeuroVision brand name and has no impact on NuVasive’s proprietary neuromonitoring technology, the company said.
The case is Neurovision Medical Products Inc et al v NuVasive Inc, Case No. 09-06988, U.S. District Court, Central District of California.
Shares of NuVasive closed at $37.36 Wednesday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Dhara Ranasinghe)